期刊文献+

依普利酮对阿霉素诱导心衰大鼠TNF-α的影响 被引量:1

Effect of Eplerenone on Serum TNF-α Levels in Adriamycin Induced Heart Failure Male Rat Models
下载PDF
导出
摘要 目的:探讨依普利酮对阿霉素诱导心衰大鼠血清TNF-α的影响及其治疗心衰的可能机制。方法:50只雄性SD大鼠随机挑选40只腹腔注射阿霉素制做心衰模型,其余10只作为正常对照组。6周后将存活的20只模型鼠随机分为2组:心力衰竭+依普利酮治疗组(n=10),给予依普利酮200mg/(kg.d)灌胃,心力衰竭组(n=10)与正常对照组大鼠(n=10)给与安慰剂(生理盐水)灌胃,12周后观测一般变化,测定大鼠心功能及血清TNF-α含量。结果:心衰组血流动力学指标与正常组相比有显著性差异(P<0.05)。治疗组血流动力学指标与心衰组相比有显著性差异(P<0.05)。心衰组TNF-α水平与正常组相比明显升高(P<0.05)。治疗组TNF-α水平与心衰组相比明显下降,有显著性差异(P<0.05)。结论:依普利酮可以降低心衰大鼠血清TNF-α的含量。 Objective To investigate the effect of eplerenone on serum TNF - α levels in adriamyein induced heart failure male rat models. Methods Fourty male rat models of adriamyein - induced heart failure were prepared with weekly intraperitoneal injection of adriarnycin (4/mg/kg) for six weeks. Twenty surviving models were randomly divided into two groups: (1)eplerenone -treated group, n = 10, treated with gavage of eplerenone 200mg/kg/d for 12 weeks (2) non - treated group n = 10. All the surriving models (group (1) n =8, group (2) n =6) were sacrificed after 12 weeks with left ventricular hemodynamie function parameters tested and sertum TNF - α levels measured. Ten male rats without adriamycin administration served as controls. Results Left ventricular hemodynamic parameters in the non - treated group were significantly worse than those in controls ( P 〈 0.05 ). The parameters in the eplerenone treated group were significantly better than those in the non - treated group ( P 〈 0.05). The serum TNF - α levels in the non - treated group were significantly higher than those in controls ( P 〈 0.05). TNF - α levels in the eplerenone group were significantly lower than those in the non - treated group ( P 〈 0.05 ). Conclusion Eplerenone could reduce the serum TNF - α levels in the rat models of heart failure.
出处 《放射免疫学杂志》 CAS 2009年第1期14-16,共3页 Journal of Radioimmanology
关键词 依普利酮 心力衰竭 肿瘤坏死因子 eplerenone, heart failure, TNF - α
  • 相关文献

参考文献9

  • 1Pitt B, Remrue W, Zannad F, et al. Eplerenone, a selective aldostetone blocker in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003,348(4) :1309.
  • 2李彦明,王吉云.抗肿瘤坏死因子-α治疗慢性心力衰竭[J].中国医刊,2007,42(7):19-21. 被引量:3
  • 3吴晓光,王冬梅.细胞因子与心力衰竭关系的研究进展[J].解放军保健医学杂志,2008,10(1):72-74. 被引量:2
  • 4Rocha R, Rudolph AE, Ffierdich GE, et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol. 2002,283 : H1802.
  • 5Satoh M, lwasaka J, Nakamura M, et al. Increased expression of tumor necrosis factor -α converting enzyme .rod tumor necrosis factor -α in peripheral blood mononuclear cells in patiems with advanced congestive heart failure. Eur J Heart Fail. 2004,6:869.
  • 6Satoh M, Ishikawa Y, Minami Y, et al. Eplerenone inhibits turnout necrosis factor a shedding process by tumour necrosis factor a converting enzyme in monocytes from patients with congestive heart failure. Scientific Letter. 2006,92:979.
  • 7Sun Y, Zhang J, Lu L, et al. Aldosterone - induced inflammation in the rat heart: role of oxidative stress. Am J Pathol. 2002 161:1773.
  • 8Kuster GM, Kotlyar E, Rude MK. Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload. Circulation. 2005, 111:420.
  • 9Hansen PR, Rieneck K, Bendtzen K. Spironolactone inhibits production of proinflammatory cytokines by human mononuclear cells. Immunol Lett. 2004, 91:87.

二级参考文献20

  • 1[9]Kanda T,Takahashi T.Interleukin-6 and cardiovascular diseases[J].Jpn Heart J,2004,45:183-193.
  • 2[10]Redevoe DL,Widawski M,Fonarow GC,et al.Interleukin-6(IL-6)expression and natural killer(NK)cell dysfunction and anergy in heart failure[J].Am J Cardiol,2004,93:1007-1011.
  • 3[12]Pan JP,Liu TY,Chiang SC,et al.The value of plasma levels of tumor necrosis factor-alpha and interleukin-6 in predicting the severity and prognosis in patients with congestive heart failure[J].J Chin Med Assoc,2004,67:222-228.
  • 4[13]Parissis JT,Adamopoulos S,Antaniades C,et al.Effects of levesimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure[J].Am J Cardiol,2004,93:1309-1312.
  • 5[14]Shioi T,Matsumori A,Matoba Y,et al.Inhibition of cytokine production by a new inotropic agent veanarinone,in human lymphocytes.T cell line,and monocytic cell line[J].Life Sci,1994,54:PL11-16.
  • 6[15]Ohtsuka T,Hamada M,Hiasa G,et al.Effects of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy[J].J Am Coll Cardiol,2001,37:412.
  • 7[16]Matsumori A,Ono K,Nishio R,et al.Amiodarone inhibits production of tumor necrosis factor-a by human mononuclear cells[J].Circulation,1997,96:1386-1389.
  • 8[17]Gullestad L,Aass H,Field JG,et al.Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure[J].Circulation,2001,103:220-225.
  • 9[18]Sliva K,Woodiwiss A,Kone VN,et al.Therapy of ischemic cardiomyopathy with the immunomolulating agent pentoxlfylline:results of a randomized study[J].Circulation,2004,109:750-755.
  • 10[19]Adamopoulos S,Parisis J,Karatzas D,et al.Physical training modulates proinflammatory cytokines and the soluble Fas/soluble Fas ligand system in patients with chronic heart failure[J].J Am Coll Cardiol,2002,39:653-663.

共引文献2

同被引文献7

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部